News
ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi® (Ropeginterferon alpha-2b)
27. 10. 2020Rare disease pioneer AOP Orphan takes over two health care companies, strengthening its position in Europe as well as Vienna as a research- and business hub.
12. 10. 2020Narcolepsy Awareness Day 2020
22. 9. 2020
Science & Innovation
From the Concept to the Drug
AOP Orphan team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
CONNECTED WORLDWIDE
Partnering
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe.